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Septic shock is the most severe clinical manifestation of me-
ningococcal disease and is predominantly seen in children
under 5 yr of age. Very limited research has been performed
to elucidate the alterations of the GH/IGF-I axis in critically
ill children. We evaluated the GH/IGF-I axis and the levels of
IGF-binding proteins (IGFBPs), IGFBP-3 protease, glucose,
insulin, and cytokines in 27 children with severe septic shock
due to meningococcal sepsis during the first 3 d after admis-
sion. The median age was 22 months (range, 4–185 months).
Eight patients died. Nonsurvivors had extremely high GH lev-
els that were significant different compared with mean GH
levels in survivors during a 6-h GH profile (131 vs. 7 mU/liter;
P < 0.01). Significant differences were found between non-
survivors and survivors for the levels of total IGF-I (2.6 vs. 5.6
nmol/liter), free IGF-I (0.003 vs. 0.012 nmol/liter), IGFBP-1 (44.3
vs. 8.9 nmol/liter), IGFBP-3 protease activity (61 vs. 32%), IL-6
(1200 vs. 50 ng/ml), and TNF (34 vs. 5.3 pg/ml; P < 0.01). The
pediatric risk of mortality score correlated significantly with
levels of IGFBP-1, IGFBP-3 protease activity, IL-6, and TNF
(r0.45 to0.69) and with levels of total IGF-I and free IGF-I
(r  0.44 and 0.55, respectively). Follow-up after 48 h in
survivors showed an increased number of GH peaks, in-
creased free IGF-I and IGFBP-3 levels, and lower IGFBP-1
levels compared with admission values. GH levels and IG-
FBP-1 levels were extremely elevated in nonsurvivors,
whereas total and free IGF-I levels were markedly decreased
and were accompanied by high levels of the cytokines IL-6 and
TNF. These values were different from those for the survi-
vors. Based on these findings and literature data a hypothet-
ical model was constructed summarizing our current knowl-
edge and understanding of the various mechanisms. (J Clin
Endocrinol Metab 87: 3118–3124, 2002)
MENINGOCOCCAL SEPTIC SHOCK is the most severeclinical manifestation of meningococcal disease and
is predominantly seen in children under 5 yr of age. This
form of meningococcal disease is characterized by a rapid
onset of disease, fever, purpura, and ultimately shock (1).
Despite improved supportive care, the mortality of menin-
gococcal septic shock has not diminished during the last few
decades and still ranges between 20–50%. Critical illness
leads to a spectrum of neuroendocrine and metabolic
changes. Alterations in the GH/IGF-I axis have been re-
ported in studies of critically ill adult patients, and it has been
postulated that these alterations are due to the development
of GH resistance (2–4). GH trials were initiated to improve
the recovery of these critically ill adult patients (5, 6). How-
ever, these trials have been cancelled, because an increased
mortality was observed in the treated patients (6). Only very
limited research has been performed to elucidate the alter-
ations of the GH/IGF-I axis in critically ill children. Recently,
we reported differences between survivors and nonsurvi-
vors regarding the adrenal and thyroid axis in children with
meningococcal sepsis (7). Understanding the insufficient pi-
tuitary-adrenal axis in nonsurvivors might be essential to
develop new diagnostics or even therapies to improve clin-
ical outcome for these children (7). The present study eval-
uated the 6-h serum GH profile and serum or plasma levels
of total IGF-I, free IGF-I, IGF-binding protein-1 (IGFBP-1),
IGFBP-3, IGFBP-3 protease, insulin, and glucose and related
them to serum cytokine levels of IL-6 and TNF during the
first 48 h of admission in the pediatric intensive care unit
(PICU) in children with septic shock due to meningococcal
sepsis.
Materials and Methods
Study protocol
Children more than 1 month and less than 18 yr of age with septic
shock and petechia/purpura requiring intensive care treatment were
enrolled in this study. The group consisted of 27 children admitted or
referred to the PICU of Sophia Children’s Hospital between July 1997
and April 1999. Patients were eligible for inclusion when they met the
following criteria: 1) presence of petechia/purpura; 2) presence of shock
for less than 6 h defined as persistent hypotension (systolic blood pres-
sure, 75 mm Hg for children between 3–12 months, 80 mm Hg for
1–5 yr, 85 mm Hg for 6–12 yr, 100 mm Hg for children older than
12 yr), or evidence of poor end-organ perfusion, defined as at least two
of the following: 1) unexplained metabolic acidosis (pH 7.3 or base
excess below 5 mmol/liter or plasma lactate levels 2.0 mmol/liter);
2) arterial hypoxia (PO2 75 mm Hg, PO2/FiO2 ratio, 250; transcu-
taneous oxygen saturation, 96%) in patients without overt cardiopul-
monary disease; 3) acute renal failure (diuresis,0.5 ml/kgh for at least
Abbreviations: ALS, Acid-labile subunit; IGFBP, IGF-binding protein;
PICU, pediatric intensive care unit; PRISM, pediatric risk of mortality.
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1 h despite acute volume loading or evidence of adequate intravascular
volume without preexisting renal disease); or 4) sudden deterioration of
the baseline mental status. The patients participated in a randomized,
double-blinded, placebo-controlled, dose-finding study of protein C
concentrate (human; Baxter-Immuno, Vienna, Austria). Protein C was
administered after the first blood sampling on admission. As protein C
does not influence the endocrine and metabolic assays or mortality, we
did not account for it in the analysis of data during admission (8). The
medical ethics committee of Erasmus University (Rotterdam, The Neth-
erlands) approved the study protocol. Informed consent was obtained
from the parents or legal representatives.
Clinical parameters
The pediatric risk of mortality (PRISM) score was calculated using the
most abnormal values for 14 physiological variables during the first 6 h
of admission. A higher score points to a higher risk of mortality (9).
Collection of blood
Arterial blood samples were collected within 2 h after admission (time
zero) and at 24 and 48 h for determination of total IGF-I, IGFBP-3,
IGFBP-1, IGFBP-3 protease, insulin, and glucose as well as routine lab-
oratory variables. A 6-h GH profile was performed in 12 randomly
selected patients. Blood samples for GH were taken every 30 min for 6 h,
starting within 2 h after admission (time zero) and after 48 h.
Hormonal assays
GH. Serum GH determinations were performed in one laboratory
(Department of Internal Medicine, Erasmus Medical Center, Rotterdam,
The Netherlands). Serum GH was measured by immunoradiometric
assay (CIS-Bio International, Gif-sur-Yvette, France; intra- and interas-
say coefficients of variation, 2.8% and 4.4%, respectively). The lower
detection limit was 0.08 mU/liter. Results were expressed in milliunits
per liter.
Analysis of GH secretion pattern in serum
The GH profiles were analyzed with the Pulsar program (10) adapted
for Quick Basic by Rosberg and Albertsson-Wikland (PC-Pulsar, 1987).
Peak selection criteria appropriate for our own assay conditions and
dataset were established before the GH profiles were analyzed (11). With
these settings the Pulsar program did not detect any peaks when 72
consecutive samples from each of 3 different plasma pools were assayed.
From the Pulsar analysis, the following values were extracted: number
of peaks, overall mean, maximal value, mean peak height, mean peak
amplitude, mean peak length, and area under the curve above zero level.
Based on Dutch consensus guidelines a normal 6-h GH profile in chil-
dren above 1 yr was defined as a profile with a mean GH level of at least
5.6 mU/liter, with well defined GH peaks returning to baseline levels
between GH pulses.
Total IGF-I, IGFBP-1, and IGFBP-3
Concentrations of total IGF-I, IGFBP-1, and IGFBP-3 in EDTA plasma
were determined by specific RIAs (Utrecht Medical Center, Utrecht, The
Netherlands). Technical details and data on stability and reproducibility
after storage of plasma and serum samples have been described previ-
ously (12, 13). The levels of plasma total IGF-I, IGFBP-1, and IGFBP-3
were expressed as nanomoles per liter. Reference values for both total
IGF-I and IGFBP-3 have been reported previously (12). Smoothed ref-
erences constructed by the LMS method were used (14). To correct for
age and gender, plasma IGF-I and IGFBP-3 levels were also expressed
as sd scores using the respective LMS normative range data.
Free IGF-I
Dissociable free serum IGF-I was measured with a commercially
available noncompetitive two-site immunoradiometric assay (Diagnos-
tics Systems Laboratories, Inc., Webster, TX). Intra- and interassay co-
efficients of variation were 10.3% and 10.7%, respectively. The detection
limit was 0.003 nmol IGF-I/liter. The concentration of free IGF-I was
expressed as nanomoles per liter.
IGFBP-3-protease
Serum IGFBP-3-protease, which degrades IGFBP-3, was determined
as described by Lamson et al. (15) and modified by Koedam et al. (16).
In brief, the substrate indicator, i.e. nonglycosylated 125I-labeled IGFBP-3
recombinantly derived from Escherichia coli, was incubated at 37 C in the
presence of the serum being tested. Subsequently, proteolysis was
visualized by SDS-PAGE and autoradiography. The amount of prote-
olysis was expressed as percentage of the intensity on the autoradio-
gram, which was associated with degradation products of IGFBP-3,
relative to the total intensity.
Insulin and glucose levels
Insulin was measured in serum with an immunoradiometric assay.
Upper and lower detection limits were 400 and 5 mU/liter, respectively.
Glucose measurements were determined on routine clinical chemistry
analyzers (Dimension ES, DuPont Medical Products, Wilmington, DE).
Based on reference values hypoglycemia was defined as a serum glucose
level below 2.6 mmol/liter, and hyperglycemia as a serum glucose
concentration above 11 mmol/liter.
IL-6 and TNF levels
IL-6 and TNF levels were measured in serum with commercial
assays (CLB, Amsterdam, The Netherlands). The detection limit (lowest
positive standard) for IL-6 was 10 103 ng/ml, and that for TNFwas
5 pg/ml.
Statistics
Statistical analysis was performed with a statistical analysis software
program (SPSS 9.0 for WINDOWS 95, SPSS, Inc., Chicago, IL). The
Mann-Whitney test was used for comparison of clinical and laboratory
tests between nonsurvivors and survivors. Wilcoxon’s signed-rank test
was used for comparison between different laboratory tests at various
time points. Spearman’s correlation coefficient was used to evaluate the
relationship between parameters. Two-tailed P  0.05 was considered
statistically significant.
Results
Twenty-seven children admitted to the PICU fulfilled the
inclusion criteria and were included in the study (17 boys and
10 girls). The median age was 22 months (range, 4–185
months). Blood cultures revealed Neisseria meningitidis in all
27 patients. Concomitant therapy during the study period
included antibiotics, plasma (fresh-frozen plasma; mean dos-
age, 100 ml/kg BW) and inotropic agents for all patients.
Eighteen patients required additional mechanical ventilatory
support and sedation with benzodiazepines. Upon admis-
sion the median PRISM score of the nonsurvivors was sig-
nificantly higher than that of the survivors (31 vs. 18, respec-
tively; Table 1). Eight children (36%) died after a median stay
on the PICU for 10 h (range, 2–40). There was a significant
difference in age between nonsurvivors and survivors (9.5 vs.
27 months; P  0.05). The various parameters of the GH/
IGF-I axis are summarized in Table 1.
Analysis of GH secretion patterns
A 6-h GH profile analysis was performed in 12 patients
within 2 h after admission during the day or at night
(Table 2). Three of these children died during the course of
their disease. On admission all 12 children showed sponta-
neous GH secretion, although the individual mean GH levels
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varied considerably but regardless of the time of the day.
Nonsurvivors had higher median values of mean GH levels
than children who survived (131 vs. 7 mU/liter; P  0.01;
Table 2). Upon admission nonsurvivors had extremely high
GH levels, whereas most survivors had normal or low GH
levels with a very limited number of small GH peaks (Fig. 1).
The median values of mean GH levels and the area under the
curve above zero level in survivors did not change signifi-
cantly between 0 and 48 h after admission, but there was a
significant difference in the number of GH peaks (two vs.
three; P  0.05; Fig. 1 and Table 2).
Total and free IGF-I levels
On admission all patients had significantly lower serum
total IGF-I levels compared with healthy peers or when levels
were adjusted for gender and age and expressed as the sd
score (Table 1 and Fig. 2). Mean total IGF-I SDS levels were
lower in the nonsurvivors compared with the survivors, but
this difference did not reach statistical significance. Nonsur-
vivors had significantly lower free IGF-I levels on admission
compared with survivors (Table 1 and Fig. 2). In five non-
survivors and one survivor free IGF-I was not detectable. A
significant negative correlation was found between the
PRISM score and the levels of total IGF-I and free IGF-I
(Table 3).
During admission the survivors showed a significant in-
crease in serum total IGF-I levels at 12 and 24 h, followed by
a significant decrease from 24 to 48 h, whereas a significant
increase was found in free IGF-I levels at 12, 24, and 48 h
(Fig. 2).
IGFBP-1 levels
On admission the nonsurvivors had extremely high me-
dian serum IGFBP-1 levels (44.3 nmol/liter), significantly
higher than those of survivors (8.9 nmol/liter; Table 1 and
Fig. 2). For comparison, normal serum IGFBP-1 levels for
nonfasted healthy subjects usually range between 1.0–2.3
nmol/liter. IGFBP-1 levels showed a significant correlation
with the PRISM score (r  0.45; P  0.01; Table 3). In
survivors the plasma levels of IGFBP-1 decreased signifi-
cantly between 0 and 48 h. IGFBP-1 levels did not correlate
with insulin levels on admission in all patients or at 24 and
48 h in those who survived. In contrast, on admission a
significant inverse relationship was found between serum
IGFBP-1 and glucose levels (r  0.45; P  0.05). This cor-
relation was not found at 24 and 48 h in those who survived.
IGFBP-3 levels
On admission both nonsurvivors and survivors had sig-
nificantly lower median serum IGFBP-3 levels, expressed as
the sd score, than their healthy peers. There was no signif-
icant difference in median serum IGFBP-3 sd score between
nonsurvivors and survivors (Table 1 and Fig. 2). A significant
increase in median IGFBP-3 sd score was found during the
course of the disease in those who survived.
IGFBP-3 protease activity
On admission the median serum IGFBP-3 protease activity
was significantly (2-fold) higher in nonsurvivors than inT
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survivors (61% vs. 32%, respectively; Table 1). IGFBP-3 pro-
tease activity correlated significantly with the PRISM score
(r  0.60; P  0.05; Table 3). The median serum IGFBP-3
protease activity of survivors did not change significantly
between 12 and 48 h, whereas a significant increase was
observed between 0 and 48 h (P  0.05).
Insulin and glucose levels
On admission nonsurvivors had significantly lower me-
dian serum insulin and glucose levels than survivors [insu-
lin, 5 vs. 13 mU/liter (P 0.01); glucose, 3.9 vs. 6.3 mmol/liter
(P  0.05)]. At that time two patients (both nonsurvivors)
suffered from hypoglycemia (2.4 and 1.6 mmol glucose/
liter), whereas two other children (both survivors) exhibited
supranormal glucose levels (11.6 and 14.3 mmol glucose/
liter). On admission the PRISM score did not correlate with
insulin and glucose levels. At 48 h the median serum insulin
levels of the survivors had increased significantly (from 13 to
19 mU/liter), whereas the median levels of glucose had not
changed (from 6.2 to 6.0 mmol/liter).
IL-6 and TNF levels
On admission nonsurvivors had significantly higher me-
dian serum levels of IL-6 and TNF than survivors [IL-6, 1200
vs. 50 ng/ml (P 0.01); TNF, 34.0 vs. 5.3 pg/ml (P 0.01)].
These levels correlated significantly with the PRISM score,
IGFBP-1 and IGFBP-3 protease (r 0.56–0.69), and the levels
of total IGF-I and free IGF-I (r  0.40 to 0.55; Table 3).
Discussion
Our study is the first to describe changes in the GH/IGF-I
axis in children with acute, life-threatening meningococcal
sepsis, showing differences between nonsurvivors and sur-
vivors. All children had septic shock, with significantly lower
serum levels of total and free IGF-I and higher serum
IGFBP-3 protease activity and serum IGFBP-1 levels com-
pared with healthy children. However, nonsurvivors, had
extremely high mean serum GH levels during a 6-h profile
and, compared with survivors, had significantly lower total
and free IGF-I levels, higher IGFBP-3 protease activity, and
IGFBP-1 levels. Our study showed that extremely high mean
plasma GH levels were highly associated with lethal out-
come. In contrast, studies in critically ill adults revealed
normal or high plasma GH levels regardless of patient out-
come (17–24).
In this study survivors had normal or low GH profiles
compared with healthy children. In contrast, nonsurviving
children had extremely elevated mean plasma GH levels,
with extreme baseline GH levels above 88–120 mU/liter,
without low trough values between GH peaks. Their mean
plasma GH levels were significantly higher than those of
survivors and were 25 times higher than those reported in
critically ill adults (17). One of the explanations for the ex-
tremely elevated plasma GH levels in nonsurviving children
might be an increased GH secretion in response to the en-
dotoxin and cytokine load (25). Furthermore, the low serum
IGF-I levels might have intensified GH production by a lack
of feedback inhibition of pituitary GH secretion. The lost
relationship between GH secretion and plasma IGF-I, which
is a characteristic feature of critical illness in adults (26), is
thus also seen in this study.
TABLE 2. Characteristics of individual children who underwent a 6-h serum GH-profile
On admission
GH profile
On admission On day 3
Sex Age(month)
Time
GH
profile
Outcome PRISMscore
IL-6
(ng/ml)
Mean GH
(mU/liter) Peak no.
AUC0
(mU/liter)
Mean GH
(mU/liter)
Peak
no.
AUC0
(mU/liter)
M 21 17.30 Survivor 18 5.0 2 56 14.4 3 167
F 52 1.30 Survivor 20 313 4.5 0 48 10.7 3 152
M 18 17.50 Survivor 27 7.4 3 74 28.5 2 313
F 185 20.00 Survivor 14 0.2 14.7 2 119
F 27 19.45 Survivor 14 41 2.7 2 31 16.2 4 203
F 32 16.00 Survivor 10 31 18.8 1 219
F 15 6.00 Survivor 18 81 3.3 1 36 42.5 3 502
M 4 2.30 Survivor 12 8 39.2 2 485 32.2 3 359
M 23 12.20 Survivor 20 64 17.7 0 207 18.1 1 215
M 24 12.10 Non-surv 37 2934 153 0 1847
M 10 19.15 Non-surv 32 1959 131 0 1549
M 5.5 20.00 Non-surv 34 1185 131 0 1555
M, Male; F, female; Non-surv, nonsurvivor; Peak no., number of GH peaks during 6-h profile; AUC0, area under the curve of GH above zero
level.
FIG. 1. Differences in mean  2 SE GH levels between nonsurvivors
and survivors on admission and survivors on d 3.
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All patients had significantly lower serum levels of total
and free IGF-I and IGFBP-3 and higher IGFBP-3 protease
activity compared with healthy children. Low serum
IGFBP-3 levels and increased serum IGFBP-3 protease ac-
tivity have also been demonstrated in critically ill adult pa-
tients (17, 27). Nonsurvivors, however, had significantly
lower total and free IGF-I levels and higher IGFBP-3 protease
activity than children who survived; however, IGFBP-3 lev-
els were not different. Because nonsurvivors had extremely
high GH levels one would have expected higher IGF-I and
IGFBP-3 levels compared with the survivors. There are a few
possible explanations for these differences. The production
of IGF-I and IGFBP-3 in the liver might be severely reduced
in nonsurvivors due to more severe perfusion disturbances,
which were reflected in high levels of serum lactate as pre-
viously reported (7). It has also been shown that levels of
cytokines, particularly TNF, which was significantly higher
in nonsurvivors, inhibit the hepatic production of IGF-I and
IGFBP-3 (28). In this study there were also significant inverse
relationships between the TNF and IL-6 levels and the
FIG. 2. Differences in levels of total IGF-I, free IGF-I, IGFBP-1, and IGFBP-3 between nonsurvivors and survivors upon admission and 12, 24,
and 48 h after admission in survivors. Error bars represent the mean and 95% confidence intervals.
TABLE 3. Non linear correlation coefficients (Spearman) between different parameters on admission
Total IGF-I Free IGF-I IGFBP-I IGFBP-3 IGFBP-3 protease IL-6 TNF-
PRISM 0.44a 0.55a 0.45a 0.19 0.60a 0.69b 0.64b
Total IGF-I 0.84b 0.48a 0.54b 0.10 0.40a 0.45a
Free IGF-I 0.50a 0.32 0.29 0.55a 0.55a
IGFBP-I 0.06 0.19 0.60b 0.59b
IGFBP-3 0.44 0.02 0.09
IGFBP-3 protease 0.66a 0.56a
IL-6 0.86b
a P  0.05 (two-tailed).
b P  0.01 (two-tailed).
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serum levels of total and free IGF-I. Furthermore, cytokines
might have inhibited GH receptor mRNA expression (29)
and will lead to reduced GH receptor function (4). As a result,
a reduction of hepatic production of IGFBP-3 and acid-labile
subunit (ALS) will occur, and less IGFBP-3 and ALS will be
available to form stable 150-kDa ternary complexes with
IGF-I in the circulation (30). Less stable 50-kDa binary IGF-
I/IGFBP-3 complexes will be formed. Consequently, influ-
enced by IGFBP-3 protease, the rate of dissociation of IGF-I
from IGFBP-3 is increased, and the distribution of serum
IGFs among the pool of 150-kDa (ternary) and 40-kDa (bi-
nary) complexes is altered (31). The higher IGFBP-3 protease
activity in nonsurvivors may serve as an attempt to increase
the bioavailability of already diminished IGF-I. Nonsurvi-
vors and survivors showed the same level of IGFBP-3, which
can be explained by the assay used, which was not able to
detect binary IGFBP-3 complexes. Thus, the total of ternary
and binary IGFBP-3 complexes in survivors might have been
higher than that in nonsurvivors.
Normally, circulating IGFBP-1 is mainly regulated by in-
sulin through inhibition of gene transcription in the liver,
constituting a major determinant of free IGF-I availability
(32, 33). In this study no correlation was found between
IGFBP-1 and insulin, which indicates that other factors might
be involved. During unfavorable metabolic conditions the
hepatocyte appears to alter the production of IGF regulatory
proteins by increasing cAMP production, which stimulates
IGFBP-1 and suppresses IGF-I and ALS production (34, 35).
In addition, in critically ill patients circulating IGFBP-1 un-
dergoes posttranslational modification and exists primarily
in a highly phosphorylated form (36). Phosphorylated
IGFBP-1 has a significantly higher affinity for circulating free
IGF-I and thus will bind more free IGF-I, thereby limiting the
hypoglycemic potential of free IGF-I in a setting of low sub-
strate availability and increased energy requirements (37,
38). As a consequence of the increased binding of circulating
free IGF-I to IGFBP-1, there is reduced IGF-I availability,
which will lead to limited IGF-I-induced glucose uptake to
the tissues (30). Thus, in nonsurvivors the elevated levels of
phosphorylated IGFBP-1 might have bound all of the se-
verely reduced circulating free IGF-I. In addition, in non-
survivors, the observed low levels of glucose and insulin (7)
decreased the availability of glucose for the cell and may
have contributed to the alteration in cell metabolism inevi-
tably leading to cell death. Furthermore, our study demon-
strated highly significant positive relationships on admission
between serum TNF and IL-6 levels and serum IGFBP-1
levels; all levels were highest in children who died. It has
previously been shown that both TNF and IL-6 can directly
stimulate IGFBP-1 production by HepG2 human hepatoma
cells (39). Increased IGFBP-1 levels have also been associated
with increased mortality risks in acutely ill adult patients
(40). Thus, very high serum IGFBP-1 levels might serve as a
predictor for lethal outcome in children with meningococcal
septic shock. We postulate that in nonsurvivors there was an
ultimate attempt to regulate the metabolism, but the phys-
iological reserves of the IGF-I/IGFBP system were totally
consumed, resulting in insufficient free IGF-I availability for
the tissues.
An important question remains of whether the extremely
elevated plasma GH levels in the nonsurvivors have dele-
terious effects. In various studies it is suggested that admin-
istration of GH leading to high plasma GH levels might
potentiate the deleterious effects of bacterial endotoxin,
thereby contributing to septic shock (6, 41). GH and many
cytokines belong to the same receptor family and share a
number of common postreceptor signaling pathways (42).
For that reason the extremely high levels of cytokines and GH
observed in our nonsurvivors might have induced either
overactivity or dysregulation of the receptors or depletion of
messengers necessary for the effective transduction of sig-
nals via the receptors or via postreceptor signaling pathways.
This might have interfered with the necessary adaptive im-
munological, metabolic, and hormonal responses, contrib-
uting to the cascade of adverse events leading to death.
During the first 48 h after admission survivors demon-
strated an increase in the number and amplitude of GH
peaks, mean GH, free IGF-I, and IGFBP-3 levels and a de-
crease in IGFBP-1 levels. These changes may represent a
mechanism to recover from sepsis and may point to resto-
ration of anabolic function.
In conclusion, our study shows that nonsurviving children
with meningococcal sepsis had extremely high levels of cy-
tokines, mean GH, and IGFBP-1, very different from levels
in those who survived. Our results indicate that meningo-
coccal sepsis induced complex pathophysiological mecha-
nisms, many of which are not yet known and which are
probably interlinked. Surviving children showed adaptive
responses aiming at increasing host defense and metabolic
substrates for survival, whereas nonsurvivors showed ex-
aggerated responses. It is not yet known why children re-
spond in either way.
Based on the extreme levels of TNF and IL-6 observed in
nonsurvivors, one might conclude that these levels depend
on the magnitude of the endotoxin load, but they might also
depend on the individual capacity to respond with effective
adaptive mechanisms. In that respect, genetic predisposition
and/or age-related maturation of the various systems might
play a role. The remarkable alterations in the GH/IGF-I axis
in the nonsurvivors raised the question of whether these
hormonal abnormalities influenced the outcome of the dis-
ease or proved to be an effect, rather than a cause, of the
pathology.
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